BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Recently, the “Specifically Targeting the ABL Myristoyl Pocket” (STAMP) inhibitor asciminib demonstrated effectiveness in heavily pretreated CML patients, especially those in the chronic phase, including those with the BCR::ABL1 T315I mutation or those who experienced ponatinib failure [8].